Aman Khera: The FDA DAP updated draft guidance is out
Aman Khera, at
“Breaking news! It’s here!
The long awaited FDA updated draft guidance is out and available for comments: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.
This draft guidance describes the form, content, and manner of diversity action plans, the applicable medical products, and clinical studies for which a diversity action plan is required, the timing and process for submitting diversity action plans, and the criteria and process by which FDA will evaluate sponsors’ requests for waivers from the requirement to submit a Diversity Action Plan.
It replaces the draft guidance for industry entitled ‘Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials,’ published April 14, 2022
FDA is issuing this guidance as mandated under section 3602 of FDORA, which requires that FDA update or issue guidance relating to the format and content of diversity action plans required by sections 505(z) and 520(g) of the FD and C Act (21 U.S.C. 355(z) and 360j(g) as amended by section 3601 of FDORA.
As an industry regulator, I’ll be taking some time to review this carefully.”
Source: Aman Khera/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023